Alzheimer's disease drug development pipeline: 2022-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Alzheimer's disease drug development pipeline: 2022

Published:2022-01 Issue:1 Volume:8 Page:
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:A&D Transl Res & Clin Interv

Author:

Cummings Jeffrey¹²,Lee Garam³,Nahed Pouyan⁴,Kambar Mina Esmail Zadeh Nojoo⁴,Zhong Kate¹²,Fonseca Jorge⁴,Taghva Kazem⁴

Affiliation:

1. Chambers‐Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences University of Nevada, Las Vegas (UNLV) Henderson Nevada USA

2. Department of Brain Health, School of Integrated Health Sciences University of Nevada, Las Vegas (UNLV) Henderson Nevada USA

3. Biogen Weston Massachusetts USA

4. Howard R. Hughes College of Engineering Department of Computer Science University of Nevada, Las Vegas (UNLV) Henderson Nevada USA

Funder

National Institute of General Medical Sciences

National Institute of Neurological Disorders and Stroke

National Institute on Aging

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/trc2.12295

Reference43 articles.

1. 2021 Alzheimer's disease facts and figures

2. Alzheimer's disease

3. Controversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab

4. Donanemab in Early Alzheimer’s Disease

5. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Cited by 388 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the therapeutic potential of Potentilla fragarioides var. major (Rosaceae) extract in Alzheimer’s disease using in vitro and in vivo models: A multi-faceted approach;Neuroscience;2024-11

2. Role of Mitochondrial Dysfunctions in Neurodegenerative Disorders: Advances in Mitochondrial Biology;Molecular Neurobiology;2024-09-13

3. Visual assessments of 11C-Pittsburgh compound-B PET vs. 18F-flutemetamol PET across the age spectrum;Nuclear Medicine Communications;2024-09-13

4. Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer’s Disease Therapeutics;ACS Pharmacology & Translational Science;2024-09-06

5. Systematic review and meta-analysis of transcranial direct current stimulation (tDCS) for global cognition in mild cognitive impairment and Alzheimer's disease;Geriatric Nursing;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3